Independent US Healthcare Provider Directory & Public Medical Database Patient Guides

Dr. Caleb J Scheckel , DO

Internal Medicine - Hematology & Oncology • Tulsa, OK

Active NPI 1447606348 Individual Practitioner Male Practitioner Accepts Medicare assignment
Practice location in NPPES

12697 E 51st St
Tulsa, OK 741466236

Call 9185055320 Location details and other listings
Medical Disclaimer

This profile restates public CMS/NPPES data; T-MedInfo gives no medical advice — consult a licensed professional, and call 911 for emergencies.

Practice Location & Contact Primary Location

Practice Address

12697 E 51st St

Tulsa, OK 741466236

Telephone 9185055320
Fax 9185053225
Organization at the Same NPPES Address or Phone
Tulsa Cancer Institute Pllc Facility NPI 1508172982

Matched by practice address or phone in NPPES. A shared address or phone does not confirm that this clinician works there.

Other Listings in Public Data

CMS Doctors and Clinicians lists 1 group name: Oklahoma Cancer Specialists And Research Institute, Llc. See the list

Source: CMS Doctors and Clinicians National Downloadable File, CMS release of October 2, 2026.

Listings do not confirm current availability, employment or a shared ownership network.

Medicare Profile & Education

Source: CMS Doctors and Clinicians National Downloadable File, CMS release of October 2, 2026

Medical School

Oklahoma State University College Of Osteopathic Medicine

Graduation Year

2016

Medicare patients

821 people with Original Medicare in 2024

Different Original Medicare patients in 2024; counts below 11 are hidden; this does not show availability or quality.

Source: CMS, Medicare Physician & Other Practitioners – by Provider, 2024.

Medicare-allowed amount

About $2,320,754 in 2024

The total amount Medicare approved for these services in 2024. It includes what Medicare paid and what patients or their other insurance owed, such as the deductible and coinsurance.

What this does not show: Medicare-allowed amount

This is not the clinician's income. Part of it can go to a clinic or group practice, staff, equipment or drugs. It is not the price you will pay.

Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2024.

Paid by Medicare

About $1,863,414 in 2024

The part of the Medicare-allowed amount that Medicare itself paid in 2024, after patients' deductibles and coinsurance.

What this does not show: Paid by Medicare

This is not the clinician's income and not a measure of quality.

Source: CMS, Medicare Physician & Other Practitioners – by Provider and Service, 2024.

30-day fills

2,004 standardized 30-day fills in 2024

CMS converts prescriptions to 30-day supplies so they can be compared. A 90-day prescription counts as about three 30-day fills.

What this does not show: 30-day fills

It is not a count of patients and not a measure of quality.

Part D drug cost

$6,803,484 in 2024

The total cost of these prescriptions in 2024, paid by Medicare drug plans, patients and other payers together.

What this does not show: Part D drug cost

A higher cost often reflects the type of medicines a specialty uses. It is not your out-of-pocket cost and not a measure of quality.

Source: CMS, Medicare Part D Prescribers – by Provider and Drug, 2024.

Open Payments general payments, program year 2025

All general payments: $107,359.12 across 84 records.

By nature of payment (3 largest of 4)

  • Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program: $59,070.42 across 18 records.
  • Consulting Fee: $38,861.25 across 13 records.
  • Travel and Lodging: $7,056.93 across 13 records.

Reporting-company totals (3 largest of 20)

  • Pfizer Inc.: $32,955.10 across 21 records.
  • BeOne Medicines USA, Inc.: $30,010.11 across 17 records.
  • AstraZeneca Pharmaceuticals LP: $29,644.79 across 20 records.

A reported payment does not necessarily mean the financial relationship is improper and is not a measure of care quality. Clinicians can review and dispute these records.

See the full table

Source: Calculated by T-MedInfo from CMS Open Payments general-payment records for program year 2025 (published June 30, 2026).

Guide: How to read an Open Payments record

Years since graduation

10 years (graduated 2016)

CMS Doctors and Clinicians data list 2016 as the year this clinician finished professional school.

What this does not show: Years since graduation

It is not the number of years in practice, and more years does not mean better care.

Source: CMS Doctors and Clinicians National Downloadable File, CMS release of October 2, 2026.

NPI first issued

2016

The year this clinician's National Provider Identifier (NPI) was issued. An NPI is a unique 10-digit ID that US health care providers use for billing.

What this does not show: NPI first issued

NPIs have been issued only since 2005, so this year is not necessarily when the clinician started practicing.

Source: CMS NPPES NPI Registry.

Accepts Medicare assignment

CMS data list this clinician as accepting Medicare assignment. This means agreeing to take the Medicare-approved amount as full payment for covered services.

Medicare assignment applies to Original Medicare. It does not tell you whether the clinician is in a Medicare Advantage plan's network, accepts other insurance, or is taking new patients.

Source: CMS Doctors and Clinicians, CMS release of October 2, 2026; Medicare.gov, “Does your provider accept Medicare as full payment?”

Guide: What Medicare assignment means

No telehealth indicator

CMS shows this indicator only when recent Medicare claims include telehealth services. The clinician may still offer telehealth; ask the office.

Source: CMS, Telehealth Indicator on Medicare Care Compare (fact sheet, January 2023); CMS Doctors and Clinicians, CMS release of October 2, 2026.

Guide: How Medicare covers telehealth

Enrolled in Medicare (PECOS)

Dr. Scheckel has a Medicare enrollment record in PECOS, the CMS system clinicians use to enroll so they can bill Medicare or order services for people with Medicare.

It does not show whether the clinician accepts assignment, is in your plan's network, or is taking new patients.

Source: CMS Medicare Fee-For-Service Public Provider Enrollment (PECOS); CMS Order and Referring file.

Guide: What Medicare enrollment (PECOS) means

Can order Medicare-covered services

CMS lists Dr. Scheckel as eligible to order or refer Medicare Part B clinical laboratory and imaging services, durable medical equipment (DME) and home health services for people with Medicare.

What this does not show: Can order Medicare-covered services

It does not mean the clinician offers these services directly.

Source: CMS Medicare Fee-For-Service Public Provider Enrollment (PECOS); CMS Order and Referring file.

Guide: What ordering and referring status means

Compared with the same specialty in Tulsa and Oklahoma

Billing and prescribing volume is not a quality rating.

Medicare Part B services

More Medicare Part B services than 75% of clinicians listed under Internal Medicine - Hematology & Oncology in Tulsa, OK (2024, 29 clinicians with data). Median for this group: 1,680. Middle half: 759 to 120,330.

More Medicare Part B services than 90% of clinicians listed under Internal Medicine - Hematology & Oncology in Oklahoma (2024, 97 clinicians with data). Median for this group: 1,278. Middle half: 629 to 2,609.

Medicare-allowed amount

A higher Medicare-allowed amount than 75% of clinicians listed under Internal Medicine - Hematology & Oncology in Tulsa, OK (2024, 29 clinicians with data). Median for this group: $119,245. Middle half: $67,645 to $2,127,115.

A higher Medicare-allowed amount than 90% of clinicians listed under Internal Medicine - Hematology & Oncology in Oklahoma (2024, 97 clinicians with data). Median for this group: $112,694. Middle half: $57,094 to $168,517.

Paid by Medicare

A higher Medicare payment amount than 75% of clinicians listed under Internal Medicine - Hematology & Oncology in Tulsa, OK (2024, 29 clinicians with data). Median for this group: $90,659. Middle half: $48,349 to $1,697,681.

A higher Medicare payment amount than 90% of clinicians listed under Internal Medicine - Hematology & Oncology in Oklahoma (2024, 97 clinicians with data). Median for this group: $82,861. Middle half: $45,217 to $122,621.

Medicare Part D prescriptions

More Part D prescriptions than 60% of clinicians listed under Internal Medicine - Hematology & Oncology in Tulsa, OK (2024, 29 clinicians with data). Median for this group: 1,260. Middle half: 817 to 2,015.

More Part D prescriptions than 70% of clinicians listed under Internal Medicine - Hematology & Oncology in Oklahoma (2024, 96 clinicians with data). Median for this group: 1,035. Middle half: 500 to 1,747.

Part D drug cost

A higher Part D drug cost than 90% of clinicians listed under Internal Medicine - Hematology & Oncology in Tulsa, OK (2024, 29 clinicians with data). Median for this group: $1,918,843. Middle half: $908,882 to $4,160,397.

A higher Part D drug cost than 90% of clinicians listed under Internal Medicine - Hematology & Oncology in Oklahoma (2024, 96 clinicians with data). Median for this group: $2,115,967. Middle half: $609,612 to $3,606,023.

36 active clinicians are listed under Internal Medicine - Hematology & Oncology with a practice address in Tulsa, OK (131 in Oklahoma).

Addresses are self-reported to NPPES and may be out of date.

Telehealth indicator in Tulsa

41.7% of these 36 clinicians have the CMS telehealth indicator.

80.6% of these 36 clinicians are listed by CMS as accepting Medicare assignment.

Sources: CMS Medicare Physician & Other Practitioners (2024), CMS Medicare Part D Prescribers (2024), CMS Open Payments (2025), CMS Doctors and Clinicians, CMS release of October 2, 2026, CMS NPPES NPI Registry. Specialty names follow the NUCC Health Care Provider Taxonomy.

Text: T-MedInfo · Report an error.

Pharma & Medical Device Financial Disclosures

Payments and other transfers of value that drug and medical device companies reported to CMS Open Payments

Open Payments · Program Year 2025
Disclosure Year:

Program year 2025 (payments made January 1 – December 31, 2025): 84 records totaling $107,359.12.

Manufacturer Payment Nature Product Type Amount ($)
BeOne Medicines USA, Inc.
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
BRUKINSA General $6,750.00
AstraZeneca Pharmaceuticals LP
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
CALQUENCE General $6,560.00
AstraZeneca Pharmaceuticals LP
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
CALQUENCE General $6,560.00
BeOne Medicines USA, Inc.
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
BRUKINSA General $6,000.00
BeOne Medicines USA, Inc.
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
BRUKINSA General $6,000.00
Pfizer Inc.
Consulting Fee
Cash or cash equivalent
ADCETRIS General $5,750.00
Pfizer Inc.
Consulting Fee
Cash or cash equivalent
ADCETRIS General $5,745.00
Pfizer Inc.
Consulting Fee
Cash or cash equivalent
ELREXFIO General $5,500.00
Pfizer Inc.
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
ADCETRIS General $5,250.00
AstraZeneca Pharmaceuticals LP
Consulting Fee
Cash or cash equivalent
— General $4,920.00
BeOne Medicines USA, Inc.
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
BRUKINSA General $4,500.00
Pfizer Inc.
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
ADCETRIS General $4,275.00
Bristol Myers Squibb Company
Consulting Fee
Cash or cash equivalent
— General $3,820.00
Bristol Myers Squibb Company
Consulting Fee
Cash or cash equivalent
— General $3,342.50
AstraZeneca Pharmaceuticals LP
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
CALQUENCE General $3,280.00
AstraZeneca Pharmaceuticals LP
Consulting Fee
Cash or cash equivalent
CALQUENCE General $2,460.00
BeOne Medicines USA, Inc.
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
BRUKINSA General $2,250.00
BeiGene USA, Inc.
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
BRUKINSA General $1,875.00
BeOne Medicines USA, Inc.
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
BRUKINSA General $1,875.00
AstraZeneca Pharmaceuticals LP
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
CALQUENCE General $1,640.00
AstraZeneca Pharmaceuticals LP
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
CALQUENCE General $1,640.00
Pfizer Inc.
Consulting Fee
Cash or cash equivalent
ELREXFIO General $1,540.00
Bristol Myers Squibb Company
Consulting Fee
Cash or cash equivalent
— General $1,432.50
Bristol Myers Squibb Company
Consulting Fee
Cash or cash equivalent
— General $1,432.50
Bristol Myers Squibb Company
Consulting Fee
Cash or cash equivalent
— General $1,193.75

(top 25 shown)

Source: CMS Open Payments, program year 2025, released June 30, 2026.

Performed Procedures & Service Volume

Services billed to Original Medicare Part B in 2024.

CMS Part B · Data Year 2024
Reporting Year:

CPT® is a registered trademark of the American Medical Association. CPT codes, descriptions and other data only are copyright 2018–2023 American Medical Association. All rights reserved. Applicable FARS/HHSARS apply. Descriptions of CPT codes are the AMA's CPT Consumer Friendly Descriptors as published by CMS in the Medicare Physician & Other Practitioners – by Provider and Service data, 2019–2024; they are plain-language summaries, not for clinical coding or documentation. HCPCS Level II codes and descriptions are from CMS. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

HCPCS Code Services Patients Submitted Charge Medicare Allowed
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml
13,320 130 $1.00 $0.13
J1439 Injection, ferric carboxymaltose, 1 mg
11,250 15 $3.00 $1.09
J9299 Injection, nivolumab, 1 mg
10,620 19 $64.00 $31.02
J9271 Injection, pembrolizumab, 1 mg
9,000 31 $114.00 $56.43
J9267 Injection, paclitaxel, 1 mg
7,675 33 $2.00 $0.10
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj
7,560 24 $110.00 $49.49
J1627 Injection, granisetron, extended-release, 0.1 mg
6,900 57 $12.00 $5.53
J0185 Injection, aprepitant, 1 mg
5,330 33 $5.00 $1.66
J9263 Injection, oxaliplatin, 0.5 mg
5,300 11 $4.00 $0.07
J1453 Injection, fosaprepitant, 1 mg
3,300 17 $5.00 $0.14
J0897 Injection, denosumab, 1 mg
2,700 24 $40.00 $25.80
J1100 Injection, dexamethasone sodium phosphate, 1 mg
2,619 160 $1.00 $0.11
J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use)
2,190 12 $10.00 $2.92
J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg
2,120 26 $100.00 $41.75
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
2,111 265 $26.00 $7.59
J9041 Injection, bortezomib, 0.1 mg
1,995 17 $116.00 $1.82
J1449 Injection, eflapegrastim-xnst, 0.1 mg
1,980 15 $88.00 $25.32
Q5126 Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg
1,980 22 $181.00 $57.71
83615 Lactate dehydrogenase (enzyme) level
1,904 248 $21.00 $5.90
83735 Magnesium level
1,903 248 $23.00 $6.54
84100 Phosphate level
1,902 248 $16.00 $4.63
84550 Uric acid level, blood
1,902 248 $15.00 $4.41
80053 Blood test, comprehensive group of blood chemicals
1,897 249 $36.00 $10.31
Q5123 Injection, rituximab-arrx, biosimilar, (riabni), 10 mg
1,890 16 $111.00 $39.28
36415 Insertion of needle into vein for collection of blood sample
1,541 251 $13.60 $8.64

(top 25 shown)

Source: CMS Part B by Provider and Service, 2024; services under 11 beneficiaries omitted by CMS. Privacy limits

Submitted charges are billed amounts, not a price quote for your visit.

Medicare Part D Prescribing Profile & Medications

Medicare Part D prescriptions filled, including refills, in 2024.

CMS Part D · Data Year 2024
Prescription Year:
Brand Name Generic Name Prescriptions Day Supply Total Cost Patients
Acyclovir Acyclovir 218 8,190 $3,217.24 45
Revlimid Lenalidomide 120 3,360 $2,275,429.05 18
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim 92 3,467 $483.70 25
Venclexta Venetoclax 90 2,550 $478,416.93 16
Ondansetron Odt Ondansetron 83 887 $1,068.03 36
Levofloxacin Levofloxacin 72 1,696 $1,024.99 32
Dexamethasone Dexamethasone 68 2,638 $1,112.01 24
Valacyclovir Valacyclovir Hcl 66 2,407 $2,141.12 —
Prednisone Prednisone 62 1,648 $236.55 29
Brukinsa Zanubrutinib 59 1,770 $716,860.29 —
Eliquis Apixaban 54 1,680 $31,262.30 15
Hydroxyurea Hydroxyurea 52 2,568 $1,259.85 13
Oxycodone Hcl Oxycodone Hcl 42 707 $529.08 16
Ondansetron Hcl Ondansetron Hcl 36 360 $297.38 13
Potassium Chloride Potassium Chloride 34 917 $547.74 17
Imbruvica Ibrutinib 32 896 $597,674.66 —
Calquence Acalabrutinib Maleate 31 930 $498,749.98 —
Pomalyst Pomalidomide 28 784 $616,690.03 —
Imatinib Mesylate Imatinib Mesylate 27 870 $2,150.39 —
Fluconazole Fluconazole 26 734 $1,463.52 13
Metoprolol Tartrate Metoprolol Tartrate 25 808 $74.70 —
Prochlorperazine Maleate Prochlorperazine Maleate 25 179 $218.08 12
Rydapt Midostaurin 25 714 $494,899.29 —
Allopurinol Allopurinol 24 641 $145.35 18
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen 22 346 $589.48 16

(top 25 shown)

Source: CMS Part D by Provider and Drug, 2024; rows below 11 claims omitted by CMS; volume isn’t quality. Privacy limits

Specialties & License Numbers Reported to NPPES

Self-certified to NPPES: 2023-03-14
Internal Medicine - Hematology & Oncology Primary Specialty

NUCC Taxonomy Code: 207RH0003X

License # reported to NPPES OK 7579

An internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered.

Internal Medicine

NUCC Taxonomy Code: 207R00000X

License # reported to NPPES AZ 007342

A physician who provides long-term, comprehensive care in the office and the hospital, managing both common and complex illness of adolescents, adults and the elderly. Internists are trained in the diagnosis and treatment of cancer, infections and diseases affecting the heart, blood, kidneys, joints and digestive, respiratory and vascular systems. They are also trained in the essentials of primary care internal medicine, which incorporates an understanding of disease prevention, wellness, substance abuse, mental health and effective treatment of common problems of the eyes, ears, skin, nervous system and reproductive organs.

Internal Medicine

NUCC Taxonomy Code: 207R00000X

License # reported to NPPES MN 65515

A physician who provides long-term, comprehensive care in the office and the hospital, managing both common and complex illness of adolescents, adults and the elderly. Internists are trained in the diagnosis and treatment of cancer, infections and diseases affecting the heart, blood, kidneys, joints and digestive, respiratory and vascular systems. They are also trained in the essentials of primary care internal medicine, which incorporates an understanding of disease prevention, wellness, substance abuse, mental health and effective treatment of common problems of the eyes, ears, skin, nervous system and reproductive organs.

Internal Medicine - Hematology & Oncology

NUCC Taxonomy Code: 207RH0003X

License # reported to NPPES MN 65515

An internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered.

Check License Status with the State Board License numbers are self-reported to NPPES; T-MedInfo does not confirm them against state records. Current status: Oklahoma State Board of Medical Licensure.
Look Up on State Board Site

Medicare (PECOS) Enrollment & Ordering Eligibility

Source: CMS PECOS
Medicare FFS Enrollment Status Medicare Enrollment on File
CMS Provider Specialty

PRACTITIONER - HEMATOLOGY/ONCOLOGY

Medicare Enrollment ID

I20220829002979

Enrollment State Jurisdiction

OK

PECOS Control ID

5092001172

Medicare Order & Referring Eligibility
Clinical Lab & Imaging (Part B) Eligible
Durable Medical Equipment (DME) Eligible
Home Health Agency (HHA) Eligible
Power Mobility Devices (PMD) Eligible

Sources: CMS Provider Enrollment and Order and Referring. Medicare enrollment is a billing status, not an accreditation or quality rating.

Medicare Group Practice Enrollments

Source: CMS Doctors and Clinicians National Downloadable File, CMS release of October 2, 2026

Oklahoma Cancer Specialists And Research Institute, Llc

12697 E 51st St, Tulsa, OK 741466236

Phone: 9185053200

Clinicians Sharing This Practice Address or Phone

Clinicians sharing this NPPES address, phone or fax; a shared contact does not mean they work together.

10 listed
Adrienne Chandler , APRN-CNP

Nurse Practitioner - Family

NPI 1265163810

Advanced Practice Registered Nurse - Certified Nurse Practitioner

Monica Davis , RD, LD

Dietitian, Registered

NPI 1093286635

Registered Dietitian, Licensed Dietitian

Dr. Alfred Jenkins , MD

Obstetrics & Gynecology - Gynecologic Oncology

NPI 1487686200

Doctor of Medicine (M.D.)

Kimberly Laskey , APRN, CNP

Nurse Practitioner - Adult Health

NPI 1548547375

Advanced Practice Registered Nurse, Certified Nurse Practitioner

Libbe Marquez , APRN AGCNS-BC

Clinical Nurse Specialist

NPI 1336719400

APRNAGCNSBC

Dr. Katherine Moxley , MD

Obstetrics & Gynecology - Gynecologic Oncology

NPI 1548308448

Doctor of Medicine (M.D.)

Career & Practice History Timeline

Changes recorded in monthly NPPES data files: addresses, names, credentials, specialties and NPI status

11 Historical Events
📍
Updated Practice Location August 15, 2022

Registered at 12697 E 51ST ST, TULSA, OK 741466236 (Tel: 9185055320)

📍
Updated Practice Location June 20, 2019

Registered at 200 1ST ST SW, ROCHESTER, MN 559050001 (Tel: 5072842511)

📍
Updated Business Mailing Address June 20, 2019

Registered at 200 1ST ST SW, ROCHESTER, MN 559050001 (Tel: 5072842511)

📍
Updated Practice Location May 16, 2018

Registered at 13400 E SHEA BLVD, SCOTTSDALE, AZ 85259 (Tel: 4803018000)

🎓
Medical Taxonomy / Specialty Registered (Primary Specialty) May 16, 2018

Internal Medicine (license number reported to NPPES: AZ 007342)

✅
NPI Profile Active May 10, 2016

NPI status registered as active in NPPES database

📍
Practice Location (Initial Record) May 10, 2016

Registered at 13400 E SHEA BLVD, SCOTTSDALE, AZ 852595452 (Tel: 4803018000)

📍
Business Mailing Address (Initial Record) May 10, 2016

Registered at 13400 E SHEA BLVD, SCOTTSDALE, AZ 852595452 (Tel: 4803018000)

👤
Provider Name / Credentials (Initial Record) May 10, 2016

Recorded as CALEB SCHECKEL, D.O.

🎓
Medical Taxonomy / Specialty Registered (Primary Specialty) May 10, 2016

Student in an Organized Health Care Education/Training Program

🟢
Initial NPI Registration & Enumeration May 10, 2016

First registered as active Individual Practitioner in NPPES Database.

No reviews have been published yet. Leave a review.

NPI Administrative Meta

NPI Number: 1447606348
Entity Type:
Individual Provider Physician, Nurse Practitioner, or Solo Healthcare Professional (Type 1 NPI)
Enumeration Date: May 10, 2016
Last Update: March 14, 2023
Sole Proprietor: No

Other Internal Medicine - Hematology & Oncology Specialists in Tulsa

All Internal Medicine - Hematology & Oncology Specialists in Tulsa

Mailing Address

200 1st St Sw

Rochester, MN 559050001

Phone: 5072842511

About This Data NPPES fields (address, phone, specialty, license) are self-reported and may be outdated; Medicare fields follow the CMS dataset named in each section. Correct directly at NPPES.